Physician profile
Ramya Vedula
NPI 1851591622
$2,394.72
in general payments reported to CMS, 2019-2025
23 companies · $178 in 2025
The $178 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $841 · 2020: $366 · 2021: $306 · 2022: $363 · 2023: $259 · 2024: $82.16 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $518.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,183.87 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $233.82 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Amgen INC. | $172.15 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $172.01 | 2019-2023 | |
| Madrigal Pharmaceuticals | $111.87 | 2025 | Rezdiffra |
| Abbvie INC. | $101.09 | 2019-2023 | Synthroid |
| Antares Pharma, INC. | $46.15 | 2021-2023 | Nocdurna, Tlando, Xyosted |
| Abbott Laboratories | $42.57 | 2020-2024 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $40.02 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $39.61 | 2019-2021 | |
| Medtronic Minimed, INC. | $28.50 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $27.05 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.25 | 2022 | |
| Eisai INC. | $23.80 | 2019 | |
| Dexcom, INC. | $21.92 | 2023 | Dexcom G6 Transmitter |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $21.19 | 2024 | Minimed 780g |
| Corcept Therapeutics | $20.10 | 2022 | |
| Bigfoot Biomedical INC | $16.48 | 2022 | |
| Sequel Med Tech, LLC | $16.16 | 2025 | Twiist |
| Janssen Pharmaceuticals, INC | $14.45 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.19 | 2021 | |
| Becton, Dickinson and Company | $12.26 | 2022 | |
| Xeris Pharmaceuticals, INC. | $12.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramya Vedula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.